Google+

Argyle is proud and protective of our high standards in ensuring the value of all content presented at our events. Strict guidelines are in place to ensure that all content presented is balanced and vendor neutral, and that the topics covered at our member events are thought leadership-focused and in line with the expectations of our members.

Argyle seeks to prevent overt sales pitches or unbalanced vendor references and provides all speakers with content presentation guidelines at the behest of our executive membership. We ask for your continued support for this policy as a way of protecting the high content reputation standards and trust that Argyle has established with its members.

Meeting Overview

Perspectives By:

Robert Cobuzzi
SVP Corporate Development
Endo Pharmaceuticals

Daniel Cohen
Vice President Corporate Development
Catalent Pharma Solutions

Chris Garabedian
President & CEO
AVI BioPharma

Adam Golden
Partner
Kaye Scholer

Milton Grannatt
VP & Head, Negotiations, Respiratory & New Growth Opportunities Global Bus. Dev.
Novartis

Jonathan Isler
Partner, Transaction Services
PwC

Ruhi Khan
VP, Business Development
Acorda Therapeutics Inc.

Anup Kharode
Director- Pharmaceutical & Life Sciences R&D Advisory Services
PwC

Sharon Kochan
Executive Vice President and GM
Perrigo Co.

Bob Little
VP Marketing
Innography

Ellen Lubman
Former Group Director, Strategic Transactions Group
Bristol-Myers Squibb

Ken Maynard
Global Head, External Innovation, Aging, Therapeutic Strategic Unit
Sanofi-Aventis

Garry Neil
Corporate Vice President
Johnson & Johnson

Adelene Perkins
President and Chief Executive Officer
Infinity Pharmaceuticals Inc.

Seth Rodner
Executive Vice President, Chief Legal Officer & Corporate Secretary
Medicis Pharmaceutical Corporation

Pol Vandenbroucke
Vice President, Development, Emerging Markets
Pfizer

Michael Wise
Partner, Vice President
A.T. Kearney

Brett Zbar
Partner
Aisling Capital


Summary:

The pharmaceutical and biotech industries are in the midst of significant change- change in the innovation process, new markets of interest and changes in the financing model. These changes have prompted continued discussion on the future of investment in the sector as well as discussion as to where new opportunities may lie.

On June 14th, when Argyle Executive Forum will host its Leadership in Pharmaceuticals and Biotechnology meeting, taking place in Manhattan, life science leaders will meet to discuss the full implications of these changes.

Argyle meetings are by invitation only. If you did not receive an invitation but would like to inquire about attendance, please click here.

*Press policies for member meetings are set at the individual session level. Some sessions may be on the record, while others are off. Please consult the meeting agenda, which will indicate which sessions are off the record. To inquire about media presence, please click here.

Date: Thursday, June 14, 2012

Time: 8:00am – 5:00pm

Location: New York, NY
*Event location will be disclosed to attendees upon completion of the registration process.

Advance registration is required for all member meetings. Registration is not available onsite.

To download the program from this member meeting please fill out the form below:

First Name


Last Name


Title


Company


Email


Phone number


back to top ↑